Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes

Novo Nordisk

Status and phase

Completed

Phase 4

Conditions

Diabetes

Diabetes Mellitus, Type 2

Treatments

Drug: Glucobay®

Drug: Glurenorm®

Drug: repaglinide

Study type

Interventional

Funder types

Industry

Identifiers

NCT00568074

AGEE-1555

Details and patient eligibility

About

This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of repaglinide and Glurenorm® and Glucobay® given as the mono-therapy in Chinese subjects being treatment-naive type 2 diabetics.

Enrollment

131 patients

Sex

All

Ages

30+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Type 2 diabetes
No previous treatment for diabetes
HbA1c: 7.0-12.0%

Exclusion criteria

Type 1 diabetes
Uncontrolled treated/untreated hypertension
Any condition that the Investigator and/or Sponsor feels would interfere with trial participation or evaluation of results
Pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures (adequate contraceptive measures are: sterilisation, intra-uterine device (IUD), oral contraceptives or barrier methods)